(eye dur SUL fase)
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, Intravenous [preservative free]:
Elaprase: 6 mg/3 mL (3 mL)
Brand Names: U.S.
Idursulfase is a recombinant form of iduronate-2-sulfatase, an enzyme needed to hydrolyze the mucopolysaccharides dermatan sulfate and heparan sulfate in various cells. Accumulation of these polysaccharides can lead to various manifestations of disease, including physical changes, CNS involvement, cardiac, respiratory, and mobility dysfunction. Replacement of this enzyme has been shown to improve walking capacity in patients with a deficiency.
Varies dependent upon age and presence of antibodies (particularly patients <7.5 years): Vss:
Children 16 months to <7.5 years: Week 1: 394 ± 423 mL/kg; Week 27: Antibody negative: 272 ± 112 mL/kg; antibody positive: 829 ± 636 mL/kg
Children ≥7.5 years, Adolescents, and Adults <27 years: Mean range: 213 to 254 mL/kg
Varies dependent upon age and presence of antibodies (particularly patients <7.5 years)
Children 16 months to <7.5 years: Week 1: 160 ± 69 minutes; Week 27: Antibody negative: 134 ± 19 minutes; antibody positive: 84 ±46 minutes
Children ≥7.5 years, Adolescents, and Adults <27 years: Mean range: 44 to 48 minutes
Use: Labeled Indications
Hunter syndrome: Replacement therapy in Hunter syndrome (mucopolysaccharidosis II; MPS II) for improvement of walking capacity
There are no contraindications listed in the manufacturer’s labeling.
Hunter syndrome (mucopolysaccharidosis II): IV: 0.5 mg/kg once weekly
Hunter syndrome (mucopolysaccharidosis II): Children ≥5 years and Adolescents: Refer to adult dosing.
Dosing: Renal Impairment
No dosage adjustment provided in manufacturer’s labeling.
Dosing: Hepatic Impairment
No dosage adjustment provided in manufacturer’s labeling.
Allow vials to reach room temperature prior to preparation. Dilute dose in NS 100 mL. Mix gently, do not shake.
Administer using an infusion set containing a 0.2 micron low protein-binding inline filter. Infuse at an initial rate of 8 mL/hour for the first 15 minutes. If tolerated, may increase rate by 8 mL/hour increments every 15 minutes; maximum infusion rate of up to 100 mL/hour. Rate may be decreased, temporarily stopped, or discontinued based on tolerance. Initial infusion should be over 3 hours; if tolerated, subsequent infusions may be gradually reduced to a 1-hour infusion. Total infusion time should not exceed 8 hours.
Stable in NS.
Store vials under refrigeration at 2˚C to 8˚C (36˚F to 46˚F). Protect from light, do not freeze or shake. Should be used immediately after dilution in NS. However, solution for infusion may be stored under refrigeration for up to 24 hours.
There are no known significant interactions.
Cardiovascular: Hypertension (25%), flushing (7% to 16%), atrial abnormality (13%)
Central nervous system: Headache (28% to 59%), malaise (22%), anxiety (13%), fatigue (13%), irritability (13%)
Dermatologic: Pruritus (25% to 28%), skin rash (19% to 32%), urticaria (16%), dermatologic disease (13%), infusion site swelling (13%), pruritic rash (13%)
Gastrointestinal: Vomiting (5% to 14%), dyspepsia (13%)
Hypersensitivity: Hypersensitivity reaction (10% to 69%)
Immunologic: Antibody development (51%; neutralizing: 41% to 79%), development of IgG antibodies (51% to 68%)
Infection: Abscess (16%)
Neuromuscular & skeletal: Arthralgia (31%), limb pain (28%), musculoskeletal disease (16%), musculoskeletal pain (13% to 16%; includes chest wall musculoskeletal pain)
Ophthalmic: Visual disturbance (22%)
Otic: Otitis (children 16 months to 4 years: 11%)
Respiratory: Wheezing (19%), pneumonia (children 16 months to 4 years: 18%)
Miscellaneous: Fever (9% to 63%), infusion-related reaction (15%), accidental injury (13%; superficial)
1% to 10%:
Cardiovascular: Tachycardia (9%)
Central nervous system: Chills (9%), dizziness (5%)
Dermatologic: Erythema (7%)
Gastrointestinal: Diarrhea (9%), nausea (5%)
Hypersensitivity: Anaphylaxis (10%)
Respiratory: Cough (9%)
<1% (Limited to important or life-threatening): Angioedema, cardiac arrhythmia, cardiac failure, cyanosis, hypotension, infection, loss of consciousness, pulmonary embolism, respiratory distress, respiratory failure, seizure
Concerns related to adverse effects:
• Hypersensitivity/anaphylactoid reactions: [U.S. Boxed Warning]: Serious hypersensitivity reactions, including fatal life-threatening anaphylactic reactions, have been reported during and within 24 hours after infusion. Anaphylaxis may present as respiratory distress, hypoxia, hypotension, urticaria, and/or tongue/throat angioedema. Monitor closely during and after infusion. Appropriate medical support should be readily available. Patients with compromised respiratory function or acute respiratory disease are at risk of respiratory disease exacerbation due to hypersensitivity; additional monitoring may be required. Discontinue immediately if anaphylactic or acute reaction occurs. Patients experiencing initial severe or refractory reactions may need prolonged monitoring. Antihistamines, corticosteroids and/or decreased infusion rates may be used to manage subsequent infusions.
• Antibody formation: Development of anti-idursulfase IgG antibodies has been reported in 51% of patients; may increase incidence of hypersensitivity reactions.
• Acute febrile/respiratory illness: Hypersensitivity reactions may occur. Use caution and consider delaying treatment in patients with compromised respiratory function or acute febrile or respiratory illness; may be at increased risk for life-threatening complications from hypersensitivity reactions.
• Fluid overload: Use with caution in patients at risk for fluid overload or in conditions where fluid restriction is indicated (eg, acute underlying respiratory illness, compromised cardiac and/or respiratory function); conditions may be exacerbated during infusion. Extended observation may be necessary for some patients.
• Genetic mutations: Use with caution in patients with severe genetic mutations (eg, complete gene deletion, large gene rearrangement, nonsense, frameshift or splice site mutations); may increase risk of hypersensitivity reactions, serious adverse reactions, and antibody development.
• Registry: Patients and healthcare providers are encouraged to participate in the Hunter Outcome Survey, intended to monitor disease progression, patient outcomes, and long-term effects of therapy. For more information, refer to www.elaprase.com or call OnePathsm at 1-866-888-0660.
Monitor for infusion-related and hypersensitivity reactions; pulmonary function, oxygen saturation; blood pressure
Pregnancy Risk Factor
Animal reproduction studies have not been conducted.
• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
• Patient may experience diarrhea, muscle pain, cough, itching, or skin irritation. Have patient report immediately to prescriber signs of infusion reaction, severe dizziness, passing out, loss of strength and energy, chills, fast breathing, flushing, tachycardia, or severe headache (HCAHPS).
• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for healthcare professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience and judgment in diagnosing, treating and advising patients.
More about idursulfase
- Other brands: Elaprase